Mesenchymal Progenitors set the homeostatic inflammatory milieu via the TAK1-NFkB axis

Marine Théret, Melina Messing, Zoe White, Tung Lin Wei, Lucas Rempel, Hamer Mark, Joshua Hashimoto, Fangfang Li, Brasssar Julyanne, Yicong Li, Elodie Sauge, Shin Samuel, Day Katie, Manjosh Uppal, Marcela Low, Christine Eisner, Shintaro Sato, Shizuo Akira, Hughes Michael, Pascal Bernatchez, Kelly M. McNagny, Fábio RossibioRxiv 2022 · DOI

TL;DR

Mesenchymal progenitors (MPs), crucial for tissue repair and immune regulation, were found to maintain a balanced inflammatory state through the TAK1-NFkB pathway. Disrupting this pathway in MPs leads to a pro-Type 2 inflammatory environment, exacerbating Th2-driven diseases like asthma while protecting against Th1/Th17-driven diseases like experimental autoimmune encephalitis.

What Problem Does This Paper Address?

Mesenchymal stromal cells (MSCs), including mesenchymal progenitors (MPs), are a promising therapeutic tool due to their immunomodulatory capabilities. However, their clinical success is hampered by a lack of understanding of their precise role in maintaining immune homeostasis under normal physiological conditions. This paper investigates how MPs, specifically through the TAK1-NFkB signaling pathway, contribute to the baseline inflammatory environment and how manipulating this pathway impacts immune responses and disease outcomes.

Methods

The study utilized a genetically engineered mouse model (HIC1△TAK1) where TAK1 was specifically deleted in Hic1-expressing mesenchymal progenitors. Key techniques included:

  • Mass Cytometry (CyTOF): To analyze a broad range of immune cell populations in various tissues and blood.
  • Flow Cytometry: To validate CyTOF findings and quantify specific immune cell populations.
  • Mesoscale and ELISA: To measure cytokine and IgE levels in serum.
  • RNA sequencing (RNAseq): To analyze the gene expression profile of skeletal muscle-resident MPs.
  • Gene Ontology (GO) analysis: To identify biological processes affected by TAK1 deletion in MPs.
  • Mouse models of disease: Experimental autoimmune encephalomyelitis (EAE) for Th1/Th17-driven disease and papain-induced allergic asthma for Th2-driven disease.
  • Genetic manipulation: Crossing HIC1△TAK1 mice with ST2-/- mice (lacking the IL-33 receptor) to investigate the role of ILC2s.
  • NF-kB pathway manipulation: Generating a mouse model with dampened NF-kB signaling in HIC1+ cells (HIC1△NEMO).

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • MPs as "Inflammatory Milieu Architects": The study reveals that MPs aren't just passive responders but actively shape the baseline inflammatory environment, maintaining a balance between Type 1 and Type 2 immunity.
  • TAK1-NFkB Axis is Crucial for Homeostasis: The constitutive activity of the TAK1-NFkB pathway in MPs is essential for preventing a systemic skew towards Type 2 inflammation.
  • ILC2s as Key Effectors: The study strongly implicates Type 2 innate lymphoid cells (ILC2s) as the primary mediators of the pro-Type 2 inflammatory phenotype observed when TAK1 is deleted in MPs.
  • Therapeutic Implications: Understanding this pathway opens avenues for "locking" MPs into a specific inflammatory state for targeted therapeutic interventions.

Key Results

  • Systemic Type 2 Inflammation: HIC1△TAK1 mice exhibited a significant increase in eosinophils and ILC2s, along with elevated Type 2 cytokines (IL-4, IL-5, IL-13) and IgE.
  • Impact on Disease Models:
    • HIC1△TAK1 mice were protected against Th1/Th17-driven EAE, showing delayed disease onset and milder symptoms.
  • HIC1△TAK1 mice showed increased sensitivity to papain-induced allergic asthma, with worsened lung function and inflammation.
  • Bone Marrow Hematopoiesis: Deletion of TAK1 in MPs shifted bone marrow hematopoiesis towards granulopoiesis, leading to increased eosinophil progenitors.
  • NF-kB Pathway Involvement: Dampening NF-kB signaling in HIC1+ cells phenocopied the HIC1△TAK1 phenotype, confirming the role of the TAK1-NFkB axis.
  • ILC2 Dependence: Blocking ILC2 activation (using ST2-/- mice) prevented the hyper-eosinophilia and Type 2 inflammatory environment in HIC1△TAK1 mice.

Limitations and Future Work

  • Complexity of MSCs: The paper acknowledges the diverse identities and functions of multipotent stromal cells, suggesting further research is needed to fully delineate their roles.
  • Therapeutic Translation: While the study highlights a potential strategy to "lock" MPs into a specific functional state, translating this into safe and effective cell therapies requires further investigation.
  • Broader Impact of TAK1: The study focuses on the TAK1-NFkB axis in MPs. Future work could explore other downstream targets of TAK1 in MPs and their contributions to immune regulation.
  • Specific Disease Contexts: While the study demonstrates impact in EAE and asthma models, further research is needed to understand how this pathway influences other inflammatory and autoimmune diseases.

Summary updated

Abstract

Summary The ability of mesenchymal stromal cells to modulate inflammation is at the basis of the ongoing interest in their therapeutic potential. Yet, reliable success in clinical trials is limited, possibly due to a limited understanding of their impact on the inflammatory milieu in physiological conditions. Here we show that, at steady state, mesenchymal progenitors regulate the balance between type 1 and type 2 inflammatory milieus by acting on innate immune cells through the TAK1-NFkB pathway. Suppressing the constitutive activity of this pathway in MPs leads to skewing of the immune system toward systemic Type 2 inflammation (Th2). These changes have significant effects on diseases with an important inflammatory component, leading to a worsening of disease in a preclinical model of Th2-dependent Asthma, and a reduction of symptoms associated with Th1/Th17-dependent experimental autoimmune encephalitis.
BibTeX
@misc{theret2022mesenchymal,
  author = {Marine Théret and Melina Messing and Zoe White and Tung Lin Wei and Lucas Rempel and Hamer Mark and Joshua Hashimoto and Fangfang Li and Brasssar Julyanne and Yicong Li and Elodie Sauge and Shin Samuel and Day Katie and Manjosh Uppal and Marcela Low and Christine Eisner and Shintaro Sato and Shizuo Akira and Hughes Michael and Pascal Bernatchez and Kelly M. McNagny and Fábio Rossi},
  title = {{Mesenchymal Progenitors set the homeostatic inflammatory milieu via the TAK1-NFkB axis}},
  year = {2022},
  doi = {10.1101/2022.12.11.519940},
  howpublished = {bioRxiv},
}
Figure